G-CSF improved infectious complications and increased ANC counts in approximately 50% of patients, while 22% of patients showed improved ANC counts with no effect on susceptibility to infections and 26% of patients failed to increase ANC counts or ameliorate infection frequency in response to G-CSF treatment. The gene discussed is CSF3; the disease is infection.